Markets:

Overview

News

Currencies

International

Treasuries

Harrow, Inc. - Common Stock (NQ:HROW)

36.55 -2.67 (-6.81%)

Streaming Delayed Price Updated: 2:28 PM EST, Mar 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Harrow, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗

March 04, 2026

Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing.

Via The Motley Fool

Topics Regulatory Compliance

Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing ↗

March 04, 2026

Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market.

Via The Motley Fool

Topics Regulatory Compliance

What's going on in today's session ↗

March 03, 2026

Via Chartmill

Harrow Inc (NASDAQ:HROW) Stock Plummets 13% After Q4 Earnings Miss ↗

March 02, 2026

Via Chartmill

HARROW INC (NASDAQ:HROW) Emerges as a High-Growth Momentum Stock with Strong Technical Setup ↗

January 03, 2026

Via Chartmill

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

Harrow To Acquire Sedation Solutions Developer Melt Pharmaceuticals – More Details Inside ↗

September 26, 2025

Via Stocktwits

Demystifying Harrow: Insights From 5 Analyst Reviews ↗

September 23, 2025

Via Benzinga

These stocks are moving in today's session ↗

March 03, 2026

Via Chartmill

Harrow (HROW) Q4 2025 Earnings Call Transcript ↗

March 03, 2026

Harrow (HROW) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Which stocks are gapping on Tuesday? ↗

March 03, 2026

Via Chartmill

These stocks are moving in today's after hours session ↗

March 02, 2026

Via Chartmill

A Preview Of Harrow's Earnings ↗

August 08, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Examining the Future: Harrow's Earnings Outlook ↗

May 07, 2025

Via Benzinga

Private Equity-Style Fund Buys $15.7 Million in Harrow Stock as Revenue Jumps 45% ↗

November 27, 2025

Harrow’s accelerating revenue and expanding product portfolio may help explain why a fundamentals-focused investment firm just made it a new position.

Via The Motley Fool

Topics Regulatory Compliance

Outset Medical, Gemini Space Station, CoreWeave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

November 11, 2025

Via Benzinga

These stocks are moving in today's after hours session ↗

November 10, 2025

After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Could Harrow's New Sedation Pill Change Millions Of Medical Procedures Forever? ↗

September 26, 2025

Harrow, Inc. (NASDAQ: HROW), a U.S.-based provider of ophthalmic disease management solutions, announced on Friday that it has agreed to acquire Melt

Via Benzinga

Tesla To Rally Around 4%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

September 23, 2025

Via Benzinga

HARROW INC (NASDAQ:HROW) Presents High Growth Momentum and Technical Breakout Opportunity ↗

August 29, 2025

Harrow Inc (HROW) is a high-growth ophthalmic pharma stock with strong revenue expansion and a bullish technical breakout setup, signaling potential upward momentum.

Via Chartmill

10 Health Care Stocks Whale Activity In Today's Session ↗

July 16, 2025

Via Benzinga

Earnings Scheduled For August 11, 2025 ↗

August 11, 2025

Via Benzinga

This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

July 11, 2025

Via Benzinga

William Blair Bullish On Harrow's High-Margin Branded Eye Drug Strategy ↗

June 11, 2025

Harrow licensed U.S. rights to FDA-approved BYQLOVI for post-surgical eye pain and adds momentum to its branded ophthalmic drug strategy.

Via Benzinga

Assessing Harrow: Insights From 4 Financial Analysts ↗

June 10, 2025

Via Benzinga

Jim Cramer Is 'OK' With Harrow, Recommends Buying This Energy Stock ↗

May 13, 2025

Jim Cramer takes a look at Harrow, Pfizer, Kinsale Capital, Manulife Financial, Iron Mountain and more on "Mad Money."

Via Benzinga

Where Harrow Stands With Analysts ↗

May 12, 2025

Via Benzinga

Harrow Health Posts Larger Loss In Q1, But Retail Enthusiasm Grows As Dry Eye Disease Drug Drives Revenue ↗

May 08, 2025

The company reported a net loss of $17.8 million, or 38 cents per share, compared to a loss of $13.6 million in the same period last year. Despite the wider loss, Harrow reiterated its 2025 revenue...

Via Stocktwits

Where Harrow Stands With Analysts ↗

April 01, 2025

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.